Securities Litigation Partner at Faruqi & Faruqi, LLP Encourages Viatris Investors to Discuss Losses
Investors who have suffered significant losses after purchasing Viatris Inc. (VTRS) securities between November 2, 2020, and March 3, 2021, are encouraged to contact securities litigation partner James (Josh) Wilson at Faruqi & Faruqi, LLP directly to discuss their potential legal options. The law firm is investigating potential claims on behalf of investors against Viatris.
Background on Viatris
Viatris is a global healthcare company that was formed through the merger of Mylan N.V. and Pfizer Inc.’s Upjohn business. The merger was completed on November 3, 2020. The company focuses on developing, manufacturing, and marketing a portfolio of branded and generic medicines.
Investigation Details
Faruqi & Faruqi, LLP’s investigation focuses on whether Viatris and certain of its executives and directors violated federal securities laws by making false and/or misleading statements and/or failed to disclose material information to investors. Specifically, the firm is investigating whether Viatris and its executives and directors misrepresented the financial impact of the merger and the company’s financial prospects.
Impact on Individual Investors
If you purchased Viatris securities during the class period and suffered significant losses, you may be entitled to compensation. It is important for you to contact a securities attorney as soon as possible to discuss your rights and potential remedies. You may be able to recover your losses through a class action lawsuit.
Global Implications
The potential implications of this investigation extend beyond individual investors. The investigation could lead to increased scrutiny of the healthcare industry, particularly with regard to mergers and acquisitions. It could also serve as a reminder to investors of the importance of conducting thorough due diligence before making investment decisions.
Conclusion
If you have suffered significant losses after purchasing Viatris securities between November 2, 2020, and March 3, 2021, contact securities litigation partner James (Josh) Wilson at Faruqi & Faruqi, LLP to discuss your potential legal options. The investigation into potential securities law violations by Viatris and its executives and directors could result in significant compensation for affected investors. Additionally, the implications of this investigation could have broader implications for the healthcare industry and the investment community as a whole.
- Contact Faruqi & Faruqi, LLP for a consultation if you suffered significant losses after purchasing Viatris securities between November 2, 2020, and March 3, 2021.
- A securities investigation into Viatris could lead to significant compensation for affected investors.
- The implications of this investigation could extend beyond individual investors and impact the healthcare industry and the investment community.
